Anti oxidant potential of Metformin and Pioglitazone in Type 2 Diabetes Mellitus: Beyond their anti glycemic effect

Diabetes & Metabolic Syndrome
R K SinghS K Singh

Abstract

Insulin sensitizers might influence oxidative stress to improve insulin resistance in diabetes mellitus. The present study was designed with the aim to study the effect of Metformin & Pioglitazone on markers of oxidative stress after 4 weeks of therapy in patients with type 2 diabetes mellitus (Type 2 DM). This was a prospective study with follow up of 4 weeks in patients with Type 2 DM. They were randomized into metformin treated group (N=20) and Pioglitazone treated group (N=20) and healthy age-matched control group (N=20). Data was presented as mean±S.D. Student "t" test, ANOVA and Pearson correlation co-efficient tests were performed to analyze the parametric data in this study. Baseline clinical characteristics of the two study groups were similar. There is a significant difference for Fasting plasma glucose (FPG) and 2h-Post Prandial Plasma Glucose (PPPG) after 30 days of metformin and pioglitazone treatment. Metformin significantly reduced MDA (p=0.041) and increased SOD (p<0.001). Pioglitazone significantly reduced MDA (p<0.001) but failed to raise SOD level (p=0.132). Mean MDA was 4.57±0.57μM/L in metformin and 2.91±0.66μM/L in pioglitazone treatment with a p-value of <0.001. Further, a similar significant difference w...Continue Reading

References

Jan 22, 2002·The Journal of Cardiovascular Nursing·Sue PenckoferKristine Florczak
Jul 7, 2005·Antioxidants & Redox Signaling·Joseph L EvansIra D Goldfine
Sep 28, 2006·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Irina RobinsonDavid S Schade
Jun 24, 2008·The American Journal of Cardiology·Bradley J WillcoxBeatriz L Rodriguez
Oct 30, 2010·Circulation Research·Ferdinando Giacco, Michael Brownlee
Feb 8, 2011·Current Diabetes Reviews·Saeid GolbidiIsmail Laher

❮ Previous
Next ❯

Citations

Dec 30, 2015·European Journal of Pharmacology·Maciej SuskiRyszard Korbut
Mar 23, 2017·European Journal of Pharmacology·Ntsoaki Annah NyanePeter Mark Oroma Owira
Apr 14, 2016·Journal of Molecular Endocrinology·Kira MeyerovichAlessandra K Cardozo
Apr 28, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Fan PingXinhua Xiao
Oct 9, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Nurul Elyani MohamadNoorjahan Banu Alitheen
Nov 6, 2020·Nutritional Neuroscience·Wasana PratchayasakulSiriporn C Chattipakorn
Aug 10, 2019·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Michael LauAlfonso E Garcia-Bennett
Feb 11, 2021·Pharmaceuticals·Józef Drzewoski, Markolf Hanefeld

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.